These results indicate that silencing BMAL1 can reverse the pro-apoptotic effect of melatonin treatment on breast cancer cells, restore their proliferative activity and glycolytic function, and thus validate from the reverse perspective that BMAL1 plays a key mediating role in the regulation of breast cancer by melatonin. The gene discussed is BMAL1; the disease is breast carcinoma.